Neratinib After Trastuzumab-Based Adjuvant Therapy in Patients from Asia with Early Stage HER2-Positive Breast Cancer

What is it about?

Neratinib reduces disease recurrences in women with early HER2-positive breast cancer, although it is not known if these findings can be applied to women from specific geographic regions because of genetic, socioeconomic and lifestyle differences. We examined the efficacy of neratinib in Asian women and found that it effectively reduced disease recurrences in patients from this region.

Featured Image